Associations between BODE Index and Systemic Inflammatory Biomarkers in COPD

Background: COPD is a multicomponent disease and systemic inflammation represents one of the possible mechanisms responsible for its systemic manifestations, including skeletal muscle weakness and cachexia. Fat-free mass index (FFMI) that reflects the skeletal muscle mass, has been shown to be associated with both dyspnoea and exercise capacity. We hypothesized that the multidimensional BODE index, that reflects the multicomponent nature of COPD, might be related to biomarkers of systemic inflammation. We further evaluated associations between FFMI and systemic inflammation. Methods: BODE index and FFMI were calculated in 222 stable COPD patients and 132 smokers or ex-smokers with normal lung function. Systemic inflammation was evaluated with the measurement of leptin, adiponectin, CRP, IL-6, and TNF-α in serum samples of COPD patients. Results: In patients with COPD, both BODE index and FFMI presented significant positive and negative associations respectively with leptin levels (R2 0.61 and 0.65, respectively), whereas FFMI presented an additional negative association with the levels of TNF-α (R2 0.38). No significant associations were observed in smokers or ex-smokers with normal lung function. Conclusions: Both BODE index and FFMI, are related to the circulating levels of leptin in patients with COPD, suggesting a possible role for leptin in the systemic component of COPD. The additional association of FFMI with TNF-α may further support a role of systemic inflammation in muscle wasting in COPD.

[1]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[2]  H. Reddel,et al.  American Thoracic Society , 2001 .

[3]  P. Bakke,et al.  Body composition and plasma levels of inflammatory biomarkers in COPD , 2010, European Respiratory Journal.

[4]  K. Kostikas,et al.  Systemic and airway inflammation and the presence of emphysema in patients with COPD. , 2010, Respiratory medicine.

[5]  K. Kostikas,et al.  Plasma leptin and adiponectin in COPD exacerbations: associations with inflammatory biomarkers. , 2010, Respiratory medicine.

[6]  P. J. Barnes,et al.  Systemic manifestations and comorbidities of COPD , 2009, European Respiratory Journal.

[7]  N. Koulouris,et al.  Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. , 2007, Chest.

[8]  T. Itoh,et al.  Elevated circulating plasma adiponectin in underweight patients with COPD. , 2007, Chest.

[9]  M. Polkey,et al.  A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease , 2007, Respiratory research.

[10]  A. A. Romanovsky,et al.  Leptin: at the crossroads of energy balance and systemic inflammation. , 2007, Progress in lipid research.

[11]  C. Russell,et al.  Acute and chronic regulation of leptin synthesis, storage, and secretion by insulin and dexamethasone in human adipose tissue. , 2007, American journal of physiology. Endocrinology and metabolism.

[12]  John R Hurst,et al.  Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. , 2006, American journal of respiratory and critical care medicine.

[13]  S. Rubin,et al.  Inflammatory markers are associated with ventilatory limitation and muscle dysfunction in obstructive lung disease in well functioning elderly subjects , 2005, Thorax.

[14]  E. Wouters,et al.  Raised CRP levels mark metabolic and functional impairment in advanced COPD , 2005, Thorax.

[15]  B. Nordestgaard,et al.  Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. , 2006, American journal of respiratory and critical care medicine.

[16]  C. Meier,et al.  Adipose tissue: a regulator of inflammation. , 2005, Best practice & research. Clinical endocrinology & metabolism.

[17]  C. Prefaut,et al.  From muscle disuse to myopathy in COPD: potential contribution of oxidative stress , 2005, European Respiratory Journal.

[18]  E. Wouters,et al.  Body composition and mortality in chronic obstructive pulmonary disease. , 2005, American Journal of Clinical Nutrition.

[19]  D. Sin,et al.  Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[20]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[21]  A. Schols Nutritional and metabolic modulation in chronic obstructive pulmonary disease management , 2003, European Respiratory Journal.

[22]  A. Schols Nutritional modulation as part of the integrated management of chronic obstructive pulmonary disease , 2003, Proceedings of the Nutrition Society.

[23]  L. Bouter,et al.  How to measure comorbidity. a critical review of available methods. , 2003, Journal of clinical epidemiology.

[24]  X. Busquets,et al.  Systemic effects of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[25]  T. Erselcan,et al.  Comparison of Body Composition Analysis Methods in Clinical Routine , 2000, Annals of Nutrition and Metabolism.

[26]  P. Jones,et al.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.

[27]  H. Saito,et al.  Circulating leptin in patients with chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[28]  E. Wouters,et al.  Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[29]  R. Rogers,et al.  Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. , 1996, American journal of respiratory and critical care medicine.

[30]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[31]  S. Heymsfield,et al.  Height-normalized indices of the body's fat-free mass and fat mass: potentially useful indicators of nutritional status. , 1990, The American journal of clinical nutrition.

[32]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[33]  H C Lukaski,et al.  Assessment of fat-free mass using bioelectrical impedance measurements of the human body. , 1985, The American journal of clinical nutrition.